Generis announces new extensions to its Pharmaceutical & Medical Devices RIM

LONDON - Feb. 16, 2021 - PRLog -- Generis, the creator of the CARA™ foundational platform for content and business process management, has today announced new extensions to its Pharmaceutical and Medical Devices Regulatory Information Management (RIM) solution for Cosmetics, Food Supplements, Food for Special Medical Purposes, and Biocidal Products.

Generis's RIM solution, on the CARA Life Science Platform, was already the most comprehensive on the market, supporting strong functionality for managing both Pharmaceutical and Medical Device products. Now it will also support the management of Cosmetics, Food Supplements, Food for Special Medical Purposes, and Biocidal Products

Companies in heavily-regulated markets like Life Sciences need solutions that can handle RIM across their product lines and where organisations have offerings spanning more than one sector, it makes sense to manage them with a single end-to-end solution, rather than a patchwork of solutions.
"Today, Life Science companies are increasingly working across additional disciplines and pioneering new forms of products beyond their traditional areas of expertise," explains James Kelleher, CEO of Generis. "Rapid prototyping and development was in progress with the rise of powerful biotechs but has been accelerated by the pandemic."

Generis can help with this as the CARA Life Science Platform, based on the company's foundational, low-code content and business process management platform, CARA, provides the flexibility to innovate at speed.

"We have leveraged this in order to continuously roll out deeper and broader functionality in our RIM solution, James says. "This will be a game-changer for businesses, large and small, trying to manage all of their regulatory product information in one platform. We have already delivered on our promise to build a strong RIM system for Medical Devices, but this expansion to the often 'overlooked' products will really help businesses to standardise and modernise their processes.

"This journey will continue with our customers, as we continue to listen and bring new capabilities to the platform," he notes. "The low-code flexibility of CARA means that we can bring these innovations to market in weeks, not months or years. I'm excited about this latest development, and the bright future we're building with our partners."

About Generis

Generis is a UK-headquartered developer of world-class Content and Regulatory Information Management technology for regulated industries.
Eight of the top 10 global life sciences companies rely on Generis' flagship Intelligent Content Services platform, CARA™ for critical document and information management, including AbbVie, AstraZeneca, Gilead, Bayer, Pfizer, and Merck KGaA.
Today Generis serves more than half a million users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety use cases to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more.

More at http://www.generiscorp.com